Source: Eur Respir J, 55 (5) 2001319; 10.1183/13993003.01319-2020
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Anh Tuan Dinh-Xuan, Guy Brusselle. F_ENO as a biomarker guide for inhaled corticosteroid step down in patients with mild-to-moderate well-controlled asthma. Eur Respir J, 55 (5) 2001319; 10.1183/13993003.01319-2020

Member's Comments

No comment yet.

Related content which might interest you: Suppression of FENO with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice? Source: ERJ Open Res, 5 (4) 00123-2019; 10.1183/23120541.00123-2019 Year: 2019 The importance of early applying inhaled corticosteroids in patients with mild bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002 Regarding the role of FENO in predicting failure after ICS reduction in mild-to-moderate asthma patients Source: Eur Respir J, 56 (2) 2002375; 10.1183/13993003.02375-2020 Year: 2020 High or standard initial dose of budesonide to control mild-to-moderate asthma? Source: Eur Respir J 2001; 17: 856-862 Year: 2001 Magnetocardiographic assessment of therapeutic efficacy of β2–agonists and corticosteroids in patients with COPD and bronchial asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008 Long-term adherence to inhaled corticosteroids and asthma control in adult-onset asthma Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Bronchodilator reversibility and short-term inhaled corticosteroid response in Japanese patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004 Control of persistent asthma patients on inhaled corticosteroids in a real-life setting Source: Annual Congress 2010 - New insights in the epidemiology of asthma Year: 2010 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Variability in asthma severity among steroid-naive patients previously receiving short-acting beta2-agonists Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003 Clinical utility of measuring FeNO to assess inhaled corticosteroid response in asthma. Source: International Congress 2017 – Airway disease and exacerbations Year: 2017 Assessing bronchodilator response in patients with asthma and COPD using 19F-MRI Source: Virtual Congress 2020 – New imaging techniques applied to old problems Year: 2020 Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma Source: Eur Respir J 2015; 45: 1273-1282 Year: 2015 Assessment of maximal airway response before and after inhaled corticosteriod treatment in new diagnosed asthma patients Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Pharmacogenetics of inhaled corticosteroid response in adults with asthma Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights Year: 2020 Are inhaled corticosteroids increasing the “load” for some patients with COPD? Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017 Year: 2017 Inhaled medication use in asthma and COPD Roma/Gypsies patients Source: Eur Respir J 2005; 26: Suppl. 49, 610s Year: 2005 Low adherence to inhaled corticosteroids/long-acting ß2-agonists and biologic treatment in severe asthmatics Source: ERJ Open Res, 6 (2) 00017-2020; 10.1183/23120541.00017-2020 Year: 2020